Crossmark

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation

Crossref DOI link: https://doi.org/10.1186/s12883-024-03629-9

Published Online: 2024-05-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Siemeling, O.

Slingerland, S.

van der Zee, S.

van Laar, T.
License Information

Text and Data Mining valid from 2024-05-01

Version of Record valid from 2024-05-01
More Information

Article History

Received: 6 February 2024

Accepted: 8 April 2024

First Online: 1 May 2024

Declarations

:

: The GRoningen Early-PD Ambroxol Treatment trial is performed in accordance with the Declaration of Helsinki. The study has been approved by the Medical Research Ethics Committee of the University Medical Center Groningen (METc UMCG) and is registered under METc 2022/179. The study has been reviewed and approved by the Dutch Central Committee on Research involving Human Subjects (CCMO) as competent authority (BI) and is registered under NL77347.042.22.For all subjects, consent to participate was obtained through a written informed consent form.

: Not applicable.

: TvL has received grant support from the MJFF, the UMCG, Menzis, Weston Brain Institute and the Dutch Brain Foundation. Consultancy fees were received from AbbVie, Britannia Pharm., Centrapharm and Neuroderm. Speaker fees were received from AbbVie, Britannia Pharm. and Eurocept.The remaining authors declare that they have no known competing interests.

Document is current

Any future updates will be listed below